These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24098503)

  • 1. Beyond cell death - antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro.
    Koehler BC; Scherr AL; Lorenz S; Urbanik T; Kautz N; Elssner C; Welte S; Bermejo JL; Jäger D; Schulze-Bergkamen H
    PLoS One; 2013; 8(10):e76446. PubMed ID: 24098503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
    Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
    Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low BCL-xL expression in triple-negative breast cancer cells favors chemotherapy efficacy, and this effect is limited by cancer-associated fibroblasts.
    Nocquet L; Roul J; Lefebvre CC; Duarte L; Campone M; Juin PP; Souazé F
    Sci Rep; 2024 Jun; 14(1):14177. PubMed ID: 38898061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and "osmotic reprogramming" in colorectal cancer.
    Knoll G; Riffelsberger P; Raats D; Kranenburg O; Ehrenschwender M
    Cell Death Dis; 2020 Apr; 11(4):257. PubMed ID: 32312973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
    Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
    PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
    Scherr AL; Mock A; Gdynia G; Schmitt N; Heilig CE; Korell F; Rhadakrishnan P; Hoffmeister P; Metzeler KH; Schulze-Osthoff K; Illert AL; Boerries M; Trojan J; Waidmann O; Falkenhorst J; Siveke J; Jost PJ; Bitzer M; Malek NP; Vecchione L; Jelas I; Brors B; Glimm H; Stenzinger A; Grekova SP; Gehrig T; Schulze-Bergkamen H; Jäger D; Schirmacher P; Heikenwalder M; Goeppert B; Schneider M; Fröhling S; Köhler BC
    Cell Death Dis; 2020 Oct; 11(10):875. PubMed ID: 33070156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer.
    Heimer S; Knoll G; Neubert P; Hammer KP; Wagner S; Bauer RJ; Jantsch J; Ehrenschwender M
    FEBS J; 2021 Mar; 288(6):1822-1838. PubMed ID: 32710568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
    Campone M; Noël B; Couriaud C; Grau M; Guillemin Y; Gautier F; Gouraud W; Charbonnel C; Campion L; Jézéquel P; Braun F; Barré B; Coqueret O; Barillé-Nion S; Juin P
    Mol Cancer; 2011 Sep; 10():110. PubMed ID: 21899728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and biological analysis of Bcl-xL expression in human osteosarcoma.
    Wang ZX; Yang JS; Pan X; Wang JR; Li J; Yin YM; De W
    Bone; 2010 Aug; 47(2):445-54. PubMed ID: 20580954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    Schulze-Bergkamen H; Ehrenberg R; Hickmann L; Vick B; Urbanik T; Schimanski CC; Berger MR; Schad A; Weber A; Heeger S; Galle PR; Moehler M
    World J Gastroenterol; 2008 Jun; 14(24):3829-40. PubMed ID: 18609706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
    Sarif Z; Tolksdorf B; Fechner H; Eberle J
    Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-x
    Hoffmeister-Wittmann P; Mock A; Nichetti F; Korell F; Heilig CE; Scherr AL; Günther M; Albrecht T; Kelmendi E; Xu K; Nader L; Kessler A; Schmitt N; Fritzsche S; Weiler S; Sobol B; Stenzinger A; Boeck S; Westphalen CB; Schulze-Osthoff K; Trojan J; Kindler T; Weichert W; Spiekermann K; Bitzer M; Folprecht G; Illert AL; Boerries M; Klauschen F; Ochsenreither S; Siveke J; Bauer S; Glimm H; Brors B; Hüllein J; Hübschmann D; Uhrig S; Horak P; Kreutzfeldt S; Banales JM; Springfeld C; Jäger D; Schirmacher P; Roessler S; Ormanns S; Goeppert B; Fröhling S; Köhler BC
    Liver Int; 2022 Dec; 42(12):2855-2870. PubMed ID: 35983950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-X
    Yao W; Bai L; Wang S; Zhai Y; Sun SY
    Neoplasia; 2022 Jul; 29():100798. PubMed ID: 35462114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
    Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
    Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells.
    Lee YJ; Hwang IS; Lee YJ; Lee CH; Kim SH; Nam HS; Choi YJ; Lee SH
    J Korean Med Sci; 2014 Nov; 29(11):1464-72. PubMed ID: 25408576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells.
    Tanaka T; Kikuchi N; Goto K; Iino M
    Apoptosis; 2016 May; 21(5):594-608. PubMed ID: 26892009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.